Teva Pharma (TEVA) Misses Q3 EPS by 6c

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.

GUIDANCE:

Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of $16-16.4 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• AeroVironment (AVAV) PT Lowered to $280 at Canaccord
• Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020